Company Analysis
Sign in

Alkermes plc (ALKS)

Nasdaq: ALKS · Pharmaceutical Preparations · Dublin 4, IE · filing with the SEC since 2011
Full chart Alerts Compare
Grade6.6
◀ Past 6.8● Present 7.2▶ Future 5.4
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

295 patents granted to the 8 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Alkermes plc’s names, not what it holds today.

Patents granted
295
290 utility, 3 design, 2 reissue, 1976 to Dec 31, 2025
Granted in 2025
19
Against 28 in 2024 and 15 in 2023
Applications published
400
24 of them in 2025
Names they are printed under
8
a subsidiary, its own name
By yearGrantedApplications published
'11'12'13'14'15'16'17'18'19'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Pharmaceuticals74
Organic fine chemistry17
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name8 counted
Alkermes Pharma Ireland Limited a subsidiary
IE, as the owner printed on each patent. 1 more under the same name are not counted (printed in US)
159 granted
50 published
Alkermes Pharma Ireland Limited a subsidiary
named as the applicant on its applications, in IE
0 granted
171 published
Alkermes, Inc. its own name
US, as the owner printed on each patent
75 granted
66 published
Flamel Ireland Limited a subsidiary
named as the applicant on its applications, in IE
0 granted
58 published
FLAMEL IRELAND LIMITED a subsidiary
IE, as the owner printed on each patent
55 granted
2 published
Alkermes, Inc. its own name
named as the applicant on its applications, in US
0 granted
43 published
Rodin Therapeutics, Inc. a subsidiary
named as the applicant on its applications, in US
0 granted
10 published
Rodin Therapeutics, Inc. a subsidiary
US, as the owner printed on each patent
6 granted
0 published
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Nov 25, 2025D1,102,889Nightly dose packet storage setFLAMEL IRELAND LIMITED
Nov 25, 202512,478,604Modified release gamma-hydroxybutyrate formulations having improved pharmacokineticsPharmaceuticalsFLAMEL IRELAND LIMITED
Oct 14, 202512,441,710Substituted piperidino compounds and related methods of treatmentOrganic fine chemistryAlkermes, Inc.
Aug 19, 202512,390,474Immediate release multilayer tabletPharmaceuticalsAlkermes Pharma Ireland Limited
May 27, 202512,311,027Pharmaceutical compositions having improved storage stabilityPharmaceuticalsAlkermes Pharma Ireland Limited
May 20, 202512,303,478Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed statePharmaceuticalsFLAMEL IRELAND LIMITED
May 13, 202512,295,926Modified release gamma-hydroxybutyrate formulations having improved pharmacokineticsPharmaceuticalsFLAMEL IRELAND LIMITED
Apr 1, 202512,263,151Modified release gamma-hydroxybutyrate formulations having improved pharmacokineticsPharmaceuticalsFLAMEL IRELAND LIMITED
Apr 1, 202512,263,150Modified release gamma-hydroxybutyrate formulations having improved pharmacokineticsPharmaceuticalsFLAMEL IRELAND LIMITED
Mar 25, 202512,257,249Methods for treating depressive symptomsOrganic fine chemistryAlkermes Pharma Ireland Limited
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Dec 25, 20252025/0387361METHODS OF ADMINISTERING GAMMA-HYDROXYBUTYRATE COMPOSITIONS WITH DIVALPROEX SODIUMPharmaceuticalsFlamel Ireland Limited
Dec 4, 20252025/0367213IMMEDIATE RELEASE MULTILAYER TABLETPharmaceuticalsAlkermes Pharma Ireland Limited
Oct 9, 20252025/0312459Pharmaceutical Compositions Having Improved Storage StabilityPharmaceuticalsAlkermes Pharma Ireland Limited
Aug 21, 20252025/0262221IMMEDIATE RELEASE MULTILAYER TABLETPharmaceuticalsAlkermes Pharma Ireland Limited
Aug 7, 20252025/0248997Aripiprazole Dosing StrategyPharmaceuticalsAlkermes Pharma Ireland Limited
Jul 17, 20252025/0230142Substituted Fused Bicyclic Compounds and Related Methods of TreatmentOrganic fine chemistryAlkermes, Inc.
Jul 17, 20252025/0230141Substituted Fused Bicyclic Compounds and Related Methods of TreatmentOrganic fine chemistryAlkermes, Inc.
Jul 10, 20252025/0223276Substituted Pyrrolidinyl And Piperidinyl Compounds And Related Methods Of TreatmentOrganic fine chemistryAlkermes, Inc.
Jul 10, 20252025/0223260Substituted Pyrrolidinyl And Piperidinyl Compounds And Related Methods Of TreatmentOrganic fine chemistryAlkermes, Inc.
Jul 3, 20252025/0214940HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHOLOGICAL DISORDERSOrganic fine chemistryAlkermes Pharma Ireland Limited
What it applied for, 2024 to 2025: Pharmaceuticals 47 · Organic fine chemistry 12.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton ALKS · research, not advice